PFE 10-Q Quarterly Report June 28, 2020 | Alphaminr

PFE 10-Q Quarter ended June 28, 2020

PFIZER INC
10-Ks and 10-Qs
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Oct. 1, 2023
10-Q
Quarter ended July 2, 2023
10-Q
Quarter ended April 2, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Oct. 2, 2022
10-Q
Quarter ended July 3, 2022
10-Q
Quarter ended April 3, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Oct. 3, 2021
10-Q
Quarter ended July 4, 2021
10-Q
Quarter ended April 4, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 27, 2020
10-Q
Quarter ended June 28, 2020
10-Q
Quarter ended March 29, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 29, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended July 1, 2018
10-Q
Quarter ended April 1, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Oct. 1, 2017
10-Q
Quarter ended July 2, 2017
10-Q
Quarter ended April 2, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Oct. 2, 2016
10-Q
Quarter ended July 3, 2016
10-Q
Quarter ended April 3, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 27, 2015
10-Q
Quarter ended June 28, 2015
10-Q
Quarter ended March 29, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 28, 2014
10-Q
Quarter ended June 29, 2014
10-Q
Quarter ended March 30, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 29, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended July 1, 2012
10-Q
Quarter ended April 1, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Oct. 2, 2011
10-Q
Quarter ended July 3, 2011
10-Q
Quarter ended April 3, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Oct. 3, 2010
10-Q
Quarter ended July 4, 2010
10-Q
Quarter ended April 4, 2010
10-K
Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on March 14, 2024
DEF 14A
Filed on March 16, 2023
DEF 14A
Filed on March 17, 2022
DEF 14A
Filed on March 12, 2021
DEF 14A
Filed on March 13, 2020
DEF 14A
Filed on March 14, 2019
DEF 14A
Filed on March 15, 2018
DEF 14A
Filed on March 16, 2017
DEF 14A
Filed on March 15, 2016
DEF 14A
Filed on March 12, 2015
DEF 14A
Filed on March 13, 2014
DEF 14A
Filed on March 14, 2013
DEF 14A
Filed on March 15, 2012
DEF 14A
Filed on March 22, 2011
DEF 14A
Filed on March 16, 2010
TABLE OF CONTENTS
Part I - Financial InformationItem 1. Financial StatementsNote 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible AssetsNote 7E. Financial Instruments: Derivative Financial Instruments and Hedging ActivitiesNote 7D. Financial Instruments:Note 1B. Basis Of Presentation and Significant Accounting Policies: Adoption Of New Accounting Standards in 2019Note 1. Basis Of Presentation and Significant Accounting PoliciesNote 1A. Basis Of Presentation and Significant Accounting Policies: Basis Of PresentationNote 2. Acquisition, Equity-method Investment and Licensing ArrangementsNote 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-reduction/productivity InitiativesNote 5D. Tax Matters: Tax ContingenciesNote 4. Other (income)/deductions NetNote 5. Tax MattersNote 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling InterestsNote 7. Financial InstrumentsNote 1E. Basis Of Presentation and Significant Accounting Policies: Fair ValueNote 17C. Segment, Geographic and Other Revenue Information: Other Revenue InformationNote 8. InventoriesNote 9. Identifiable Intangible Assets and GoodwillNote 10. Pension and Postretirement Benefit PlansNote 11. EquityNote 12. Earnings Per Common Share Attributable To Pfizer Inc. Common ShareholdersNote 13. Contingencies and Certain CommitmentsNote 13a3Note 13a2Note 13a 2. Contingencies and Certain Commitments: Legal Proceedings Product Litigation ZantacNote 1D. Basis Of Presentation and Significant Accounting Policies: AcquisitionNote 14. Segment, Geographic and Other Revenue InformationItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsNote 7D. Financial Instruments: Long-term DebtNote 13a1Note 2C. Acquisition, Equity-method Investment and Licensing Arrangements: Licensing ArrangementsNote 1C. Basis Of Presentation and Significant Accounting Policies: Estimates and AssumptionsNote 1C. Basis Of Presentation and Significant Accounting Policies: Revenues and Trade Accounts ReceivableNote 5A. Tax Matters: Taxes on Income From Continuing OperationsNote 12. EquityItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II - Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits

Exhibits

Exhibit 2.1 - Amendment No. 1, dated as of May 29, 2020, to the Business Combination Agreement, dated as of July 29, 2019, by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Business Combination Agreement). Exhibit 2.2 - Amendment No. 2, dated as of May 29, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Separation and Distribution Agreement). Exhibit 4.1 - Fourth Supplemental Indenture, dated May 28, 2020, between Pfizer Inc. and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 28, 2020 (File No. 001-03619). Exhibit 10.1 Time Sharing Agreement, dated July 9, 2020, by and between Pfizer Inc. and Albert Bourla. Exhibit 15 - Accountants Acknowledgment. Exhibit 31.1 - Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 31.2 - Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 32.1 - Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 32.2 - Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.